SkinBioTherapeutics
SBTX · AIM · Health Care · mcap £15m · 5.8p 3 open situations →
Open · 3
Board and management changes
CEO Ashman resigned on 13 Feb 2026 and Parsonage became Interim CEO on 2 Mar. Chairman Hunt and NED Prescott left on 8 June and Levett became interim Chair. Anita Slater joined as interim non-Board CFO on 24 Aug. On 22 Sep 2026 Parsonage became permanent CEO and Levett permanent Chair. NED talks are advanced.
- Finance team
- Interim CFO Anita Slater starts 24 August 2026 to hand over with an interim finance team 24 Aug 2026 ↗
- Next milestone
- Business update by mid-September 2026 24 Aug 2026 ↗
- CEO
- Rachel Parsonage made permanent on 22 September 2026; Interim CEO since March 2026 22 Sep 2026 ↗
- Chair
- Alyson Levett permanent Non-Executive Chair; remains interim Audit & Risk Committee chair 22 Sep 2026 ↗
- Interim CFO
- Anita Slater, non-Board, started 24 August 2026 22 Sep 2026 ↗
- Board
- Hunt and Prescott left 8 June 2026; Levett interim Chair; Board of Levett, Parsonage, Bertram 8 Jun 2026 ↗
Next: Announce additional Non-Executive Director appointment
- 22 Sep 2026 Permanent leadership in place; remediation continues
- 24 Aug 2026 Findings published; finance team being rebuilt
- 8 Jun 2026 Findings published; Chair and NED exit, board reshaped
- 28 May 2026 Investigation complete; findings not yet published
FY25 accounts restatement and financial review
Led to Board and management changes – CEO and Chair made permanent; NED imminent
On 16 Feb 2026 the Board flagged an FY25 restatement. Shares were suspended on 1 Apr after the HY26 deadline was missed. On 8 June, HY26 and restated unaudited FY25 results were published: revenue £3.87m (from £4.64m) and adjusted EBITDA loss £1.40m. Trading resumed. Cash fell to £1.5m by 31 May.
- Royalty income
- £0.77m accrued in FY25 expected to be removed (flagged 16 Feb 2026) 28 May 2026 ↗
- Restated FY25
- Unaudited restated FY25 results to be published with HY26 results 28 May 2026 ↗
- Auditor
- Saffrey LLP appointed 28 May 2026 for FY26 after competitive tender; Gravita Audit II is outgoing 28 May 2026 ↗
- Restated revenue
- FY25 £3.87m from £4.64m; £0.77m royalty income removed 8 Jun 2026 ↗
- Restated EBITDA
- Adjusted EBITDA loss £1.40m from £0.41m; operating loss £2.13m from £1.12m 8 Jun 2026 ↗
- Audit
- Restated FY25 to be audited by Saffery with FY26 accounts 8 Jun 2026 ↗
Next: Audit of restated FY25 by Saffery with FY26 accounts
- 8 Jun 2026 Restated results published; shares restored 8 June
- 28 May 2026 Investigation complete; results awaited, shares suspended
- 1 Apr 2026 Shares suspended from 1 April; review ongoing
- 20 Mar 2026 Review ongoing; HY26 results delayed; suspension expected 1 April
Mark H Dixon and Diana Dixon towards control
Mark H Dixon and Diana Dixon raised its stake in SkinBioTherapeutics from 0% to 26.971% on 12 May 2026, crossing 25%.
- 12 May 2026 26.971%
Closed · 1
Company filings. Not investment advice.